Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
ConditionMacular Degeneration
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-80
SponsorScott Raymond
About this trial
The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
50-80 years of age
All genders
Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes
Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
Disqualifiers
Poor image quality that limits quantification
GA extending beyond the borders of the SDOCT field of view.
Bilateral symmetric geographic atrophy.
Diagnosis of wet AMD.
Trial population
This prospective study will enroll 30 patients from 50-80 years of age with geographic atrophy in one eye and mild to moderate AMD in the fellow eye according to International Classification of Disease (ICD) codes treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
To demonstrate the ability to quantify ophthalmic artery stenosis using a commercially available, non-invasive imaging modality, PC-CTA.
Time frame
From enrollment to the end of the 12-month study period.Secondary outcomes
1
To provide compelling evidence for a connection between ophthalmic artery stenosis and OCT markers of dry AMD disease severity and progression.
Time frame
From enrollment to the end of the 12-month study period.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Scott Raymond
Lead sponsor
The Cleveland Clinic
Sponsor institution
Source ClinicalTrials.gov